Hyderabad-based Bharat Biotech on Friday released study results of its Covid-19 vaccine candidate Covaxin , which is currently in Phase I/II human trials. "These results demonstrate the protective efficacy in a live viral challenge model," said Bharat Biotech. Bharat Biotech proudly announces the animal study results of COVAXIN™ - These results demonstrate the protective efficacy in a live viral challenge model. A tw-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally). Thus, preventing infection and disease in the primates upon high amounts of exposure to live SARS-CoV-2 virus," Bharat Biotech summarised in its report.

Source: Mint September 12, 2020 13:54 UTC